GLOBAL PARTNER TO PHARMA, BIOTECH AND HEALTHCARE Global Partner to Pharma & Biotech Mawdsleys Specialty Pharma (MSP) partners with Pharma & Biotech companies to deliver pre-license named patient programmes, registration and commercialisation of pharma products. Product licensing: we offer a full turnkey product registration and market access service for pharmaceutical and biotech companies in our core territories of UK, Brazil and Israel. Named Patient Programmes: working with pharmaceutical companies and healthcare providers, to provide physicians and patients access (in accordance with regulatory requirements) to medicines not approved in their home country, through a fully managed offering. 30,000 shipments to over 1,000 hospitals in 6 continents each year Named Patient Programmes delivered into 47 countries including 21 of EU 27 Working with 80+ Pharma & Biotech partners Regional focus On EU and LATAM 3 Global Offices Product Licensing, Market Access and Named Patient Supply Delivered through our 3 Global Offices Visit Country Website Visit Country Website Pharma Healthcare Service Provider with a 200 year history Founded in 1825, Mawdsleys is the largest independent supplier of both unlicensed and licensed medicines to the National Health Service. Mawdsleys has expanded its global presence with operations in Brazil and Israel and continues to develop into new territories internationally. We have expertise in all areas of the pharmaceutical supply chain, from providing physicians and their patients access to unlicensed medicines and third party distribution, to in-licensing products in territories. Our global infrastructure and expertise in country-specific regulatory systems mean we are ideally placed to ensure patients all over the world get the medicines they need, when they need them. Niche Pharmaceuticals and Rare Genetic Diseases are our fields of expertise. Rare diseases affect a very small percentage of each population in a country, but most are associated with life-long disability, often starting in childhood. Many of these rare diseases are chronic, degenerative and potentially life-threatening conditions, often under-diagnosed or diagnosed too late. A supportive, dedicated framework has been set up in the USA, EMA and many others geographies to promote a greater understanding of these diseases, stimulate more public and private research and to encourage innovative biopharma companies to develop and make available breakthrough treatments for some of these diseases. Access to these products can be complex, challenging and costly. For over 15 years, Mawdsleys has been the reference partner for many physicians and their patients to source the products patients need as quickly as possible whilst ensuring compliance with regulatory systems. With its well-established Unlicensed Medicines organisation in more than 52 countries (including Europe, Brazil, Israel), Mawdsleys Specialty Pharma has the expertise and resource to source niche medicines that are not licensed or readily available for the patients suffering from these rare diseases. In many cases, Mawdsleys Specialty Pharma is also able to help patients access funding for these important but costly medicines. Countries we supply, source and licence medicines for Countries we operate in Supply Source License/Commercialise Contact us First Name* Last Name* Email* Company Enquiry CAPTCHA What goes up must come:* COMPANY About Us Latest News SERVICES Secondary Care Services Pre Wholesale Services Pharmaceutical Logistics Pharma Services POLICIES & LEGAL STATEMENTS Privacy Policy Cookie Policy Gender Pay Gap Info Modern Slavery Act Statement Mawdsleys Brooks Retirement Benefit Scheme Tax Strategy Section 172 (1) Statement CONTACT Number 3 South Langworthy Road Salford M50 2PW Mawdsleys Online 3PL Client Portal Login © Mawdsley-Brooks & Co. Ltd. Registered in the England, No. 44701. Sitemap Website & SEO by Tetraza Digital Ltd